Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Male Sexual Response: Erection & Ejaculation01:17

Male Sexual Response: Erection & Ejaculation

Sexual stimulation can take various forms, such as physical touch and visual or auditory cues. When this happens, the parasympathetic reflex in the sacral portion of the spinal cord is activated. This reflex stimulates the release of nitric oxide (NO), which then dilates the arterioles in the penis, increasing blood flow to the erectile tissues - the corpora cavernosa and corpus spongiosum.
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
Infertility in Males01:23

Infertility in Males

Male infertility affects millions of couples worldwide, arising from various factors that impact different stages of the reproductive process. An endocrine imbalance resulting from conditions like hypogonadism, Klinefelter syndrome, or pituitary disorders can disrupt hormone levels and reduce sperm production. Testicular defects, such as tumors, cryptorchidism, atrophic testes, abnormal sperm morphology, and low sperm count or motility, may arise due to genetic factors, structural...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Penis01:29

Penis

The penis serves a dual role in sexual reproduction and urination. It consists of three main regions: the glans penis, the body, and the root, each with distinct functions and unique anatomical features.
Anatomy of the Penis
The glans penis, or the head, is the terminal part of the penis and houses the external urethral orifice, the exit point for urine and semen. Covered by the prepuce, or foreskin, the glans is noted for its sensitivity and plays a key role in sexual pleasure. The body of the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erectile dysfunction and Peyronie's disease: from biologics to nanomedicine-enabled therapies.

Sexual medicine·2026
Same author

From fibrosis to restoration: the multimodal 3 Ts protocol for Peyronie's disease.

International journal of impotence research·2026
Same author

Low-intensity shockwave therapy for erectile dysfunction due to diabetes mellitus or coronary artery disease: An individual participant data meta-analysis from a single center.

Andrology·2025
Same author

The role of abdominal muscle training in combination with pelvic floor muscle training to treat female urinary incontinence - a pilot 12-week study.

Central European journal of urology·2024
Same author

The recommended treatment protocol for low-intensity shockwave therapy based on the severity of erectile dysfunction.

International journal of impotence research·2024
Same author

Global Practice Patterns in the Evaluation of Non-Obstructive Azoospermia: Results of a World-Wide Survey and Expert Recommendations.

The world journal of men's health·2024
Same journal

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same journal

Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer: Recurrent High-risk NMIBC: One Bladder, Choose Wisely.

European urology·2026
Same journal

Re: Dries Develtere, Riccardo Bertolo. Cumulative Genitourinary Toxicity After Prostate Radiotherapy: High-Level Long-Term Randomized Evidence. J Clin Oncol. Online ahead of print. http://dx.doi.org/10.1200/JCO-26-00436.

European urology·2026
Same journal

In Memory of Paul Mitrofanoff (1934-2025).

European urology·2026
Same journal

Re: McKay RR, Pal S, Xie W, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert Consensus on the Management of Renal Cell and Urinary Tract Cancers. CA Cancer J Clin 2026;76:e70052.

European urology·2026
Same journal

Re: Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-year Outcomes from a Pooled Analysis of the FASTRACK Trials.

European urology·2026
See all related articles

Related Experiment Video

Updated: Jun 15, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation.

Konstantinos Hatzimouratidis1, Edouard Amar, Ian Eardley

  • 12nd Department of Urology, Aristotle University of Thessaloniki, Thessaloniki, Greece. kchatzim@med.auth.gr

European Urology
|March 2, 2010
PubMed
Summary
This summary is machine-generated.

Updated European guidelines for erectile dysfunction (ED) and premature ejaculation (PE) highlight prevalent conditions. Treatments include PDE5 inhibitors for ED and pharmacotherapy for PE, with varying efficacy and recurrence rates.

Related Experiment Videos

Last Updated: Jun 15, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Area of Science:

  • Urology
  • Men's Health
  • Sexual Medicine

Background:

  • Erectile dysfunction (ED) and premature ejaculation (PE) are the most common male sexual dysfunctions.
  • ED affects 5-20% of men, sharing risk factors with cardiovascular disease.
  • PE affects 20-30% of men and can be lifelong or acquired.

Purpose of the Study:

  • To present the updated European Association of Urology (EAU) guidelines for ED and PE.
  • Provide current evidence-based recommendations for diagnosis and treatment.
  • Consolidate information for healthcare professionals.

Main Methods:

  • Systematic review of recent literature on ED and PE epidemiology, diagnosis, and treatment.
  • Assignment of levels of evidence and grades of recommendation.
  • Analysis of diagnostic criteria and therapeutic options.

Main Results:

  • ED diagnosis relies on history, questionnaires, and tailored physical/lab tests; phosphodiesterase type 5 inhibitors (PDE5-Is) are first-line treatments.
  • Alternative ED treatments include injections, intraurethral suppositories, vacuum devices, or prostheses for non-responders.
  • PE diagnosis involves history assessing ejaculatory latency, control, and distress; pharmacotherapy (SSRIs, topical anesthetics, dapoxetine) and behavioral techniques are primary treatments.

Conclusions:

  • The EAU guidelines offer a comprehensive summary of current knowledge on ED and PE.
  • Updated recommendations guide clinical practice for managing these prevalent male sexual dysfunctions.
  • Extended guideline versions are available online for further reference.